Eliem Therapeutics Inc.

03/21/2023 | Press release | Distributed by Public on 03/21/2023 08:22

Initial Statement of Beneficial Ownership - Form 3

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Pimblett Emily
2. Date of Event Requiring Statement (Month/Day/Year)
2023-03-13
3. Issuer Name and Ticker or Trading Symbol
Eliem Therapeutics, Inc. [ELYM]
(Last) (First) (Middle)
C/O ELIEM THERAPEUTICS, INC. , 23515 NE NOVELTY HILL RD, STE. B221 #125
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Chief Accounting Officer /
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)
REDMOND WA 98053
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security 2. Amount of Securities Beneficially Owned 3. Ownership Form: Direct (D) or Indirect (I) 4. Nature of Indirect Beneficial Ownership
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Date Exercisable and Expiration Date 3. Title and Amount of Securities Underlying Derivative Security 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 6. Nature of Indirect Beneficial Ownership
Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Pimblett Emily
C/O ELIEM THERAPEUTICS, INC.
23515 NE NOVELTY HILL RD, STE. B221 #125
REDMOND, WA98053


Chief Accounting Officer

Signatures

/s/ Brian Woodard, Attorney-in-Fact 2023-03-21
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of March 26, 2021 (the "March 2021 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the March 2021 Vesting Commencement Date thereafter for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the March 2021 Vesting Commencement Date.
(2) The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of January 27, 2022 (the "January 2022 Vesting Commencement Date") for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the January 2022 Vesting Commencement Date.
(3) The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "October 2022 Vesting Commencement Date") for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the October 2022 Vesting Commencement Date.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.